Topics:

All Content

In this video from MBCC we discuss a poster presentation on genomic and protein alterations in 126 triple-negative metaplastic breast cancers.

Bevacizumab as first-line therapy for metastatic CRC equated to an incremental cost-effectiveness ratio of more than half a million dollars per QALY.

A physician’s age may have an effect on his or her opinions about the effectiveness of breast cancer screening methods, including self-exam and mammography.

Women with hormone receptor-positive breast cancer may be more scared, anxious, or concerned about treatment-related adverse events and cancer symptoms.

At MBCC, one presenter made the argument for screening mammography for all women starting at the age of 40, despite the controversy surrounding the topic.

This slide show includes some of the top highlights from the 2015 ASCO Genitourinary Cancers Symposium, including a study that examined the risk of aggressive prostate cancer in testicular cancer survivors and more.

According to a presentation at MBCC, modern breast cancer staging systems should include grade, estrogen receptor status, and possibly other biologic markers.

Intermediate-risk prostate cancer patients managed with surveillance had worse outcomes compared with low-risk prostate cancer patients managed with surveillance.

High-dose radiation therapy did not improve overall survival compared with the standard dose in stage II localized prostate cancer, but did show some benefits.

Women with breast cancer who received first-line eribulin were able to stay on treatment longer and had better outcomes when they received dose modifications.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.